The natural history of C. trachomatis urethral infections in men who have sex with women
Stephen Jordan
Primary Investigator
Brief description of study
What is the purpose of this study?
Chlamydia is the most common bacterial sexually transmitted infection (STI) in the United States and is caused by the bacteria Chlamydia trachomatis, or “CT” for short. CT infects both men and women. The purpose of this study is to understand what causes some men to resist CT infection, spontaneously clear CT, and some to resist antibiotic cure so we can design a vaccine and lower CT rates in both men and women.
We will compare samples that we collect from men who are being treated for Chlamydia to healthy samples to further study sexually-transmitted co-infections and the immune system.
Who can take part?
We are currently looking for healthy adult males (ages 18 and older) to participate.
Detailed description of study
What Happens During Study Participation
- Study participation consists of one clinic visit that will last approximately 30 minutes.
- The study visit will take place in the Bell Flower Clinic (BFC) in Indianapolis, IN or the IU Infectious Diseases Research area of the 5th 3rd Building, which is just down the hall from the BFC.
- The study visit will involve questions about medical/health history, a physical examination and collection of blood, swabs, urine and saliva.
Incentive/Compensation
- Participants will receive a $50 gift card for completing the study visit.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Healthy
-
Age: 18 years - 100 years
-
Gender: Male
Inclusion Criteria:
- Cisgender men
- Healthy
- Self-identify as heterosexual
Exclusion Criteria:
- Urogenital symptoms
History of an STI
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
